Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | FADS1 | O60427 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2901758 | 0.92 | GRM2 (0.55) | GRM2HTR2AFADS1PRSS12AOC3 | |
| SCHEMBL2901760 | 0.92 | GRM2 (0.55) | GRM2HTR2AFADS1PRSS12AOC3 | |
| SCHEMBL2901470 | 0.92 | GRM2 (0.55) | GRM2HTR2AFADS1LTA4HPRSS12 | |
| SCHEMBL5475797 | 0.92 | GRM2 (0.55) | GRM2HTR2AFADS1LTA4HPRSS12 | |
| SCHEMBL2901376 | 0.86 | GRM2 (0.53) | GRM2HTR2AFADS1LTA4HPRSS12 | |
| SCHEMBL2896650 | 0.86 | GRM2 (0.53) | GRM2HTR2AFADS1LTA4HPRSS12 | |
| SCHEMBL4974925 | 0.84 | GRM2 (0.48) | GRM2HTR2AFADS1LTA4HPRSS12 | |
| SCHEMBL2900786 | 0.84 | GRM2 (0.60) | GRM2HTR2AFADS1LTA4HPRSS12 | |
| SCHEMBL5474982 | 0.84 | GRM2 (0.60) | GRM2HTR2AFADS1LTA4HPRSS12 | |
| SCHEMBL2896644 | 0.83 | GRM2 (0.53) | GRM2HTR2AFADS1LTA4HPRSS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885HTR2A 451/4885FADS1 4353/4885 |
| US-20090012089-A1 | Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | GRM2 3/4885HTR2A 451/4885FADS1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.